Value Creation Capital (VCC) invests in CryoCloud to support the future of cryo-EM data analysis

We’re excited to announce our investment in CryoCloud, the first SaaS platform for cryo-electron microscopy (cryo-EM) analysis. CryoCloud recently raised a €2M Seed round to expand its product automation and scale its international user base. The round was led by Nina Capital, with participation from Value Creation Capital, ROM Utrecht, and Utrecht Health Seed Fund.

CryoCloud is building critical infrastructure for one of the most promising technologies in modern drug development. Its cloud-based solution removes major barriers to cryo-EM by automating complex data analysis and enabling researchers to process terabytes of data in hours instead of months. The platform has already attracted users in over 25 countries across academia, biotech, and pharma.

Why we invested
At VCC, we look for strong teams solving real problems with scalable, high-impact technology. CryoCloud fits this vision perfectly.

“CryoCloud is a high-potential company tackling a real challenge in cryo-EM. By lowering the barriers to entry for researchers and simplifying complex data analysis, they are making a meaningful impact on scientific accessibility. Their innovative approach, technical strength, and thoughtful execution make them a standout team, and we’re proud to support them as they scale.”
— Jorinde Hoek, Investment Manager at VCC

Cryo-EM is a Nobel Prize–winning imaging technique that is increasingly essential for structure-based drug design. Drugs developed using cryo-EM have significantly higher success rates in early stages, yet the high computational demands have historically limited its accessibility. CryoCloud’s fully automated SaaS solution changes that by offering scalable infrastructure, machine learning–powered analysis, and secure, easy-to-use workflows.

The market for cryo-EM services is growing rapidly, expected to reach €1 billion per year in Europe alone. As cryo-EM becomes a foundational tool in drug discovery, CryoCloud is well-positioned to lead in this space.

We look forward to working closely with the CryoCloud team as they continue to grow and drive scientific innovation.

About CryoCloud
Founded in 2021 in Utrecht by Robert Englmeier, PhD, Ilja Gubins, and Boy Persoon, CryoCloud combines deep expertise in cryo-EM, machine learning, and software development. The company is ISO27001 certified and serves a global customer base across life sciences.